His primary scientific interests are in T cell, Cytotoxic T cell, Immunology, Molecular biology and CD28. His studies in T cell integrate themes in fields like Cell, Receptor, Homing and Cell biology. The Cytotoxic T cell study combines topics in areas such as CD8 and Antigen.
Thomas Hünig works mostly in the field of Molecular biology, limiting it down to topics relating to Epitope and, in certain cases, Cell surface receptor, Monoclonal antibody and CD3. His biological study spans a wide range of topics, including CTLA-4 and ZAP70, T-cell receptor. His Interleukin 21 research is multidisciplinary, relying on both IL-2 receptor and Antigen-presenting cell.
Immunology, Molecular biology, T cell, CD28 and Cytotoxic T cell are his primary areas of study. His Molecular biology study integrates concerns from other disciplines, such as T lymphocyte, T-cell receptor, Epitope, Monoclonal antibody and Major histocompatibility complex. His T cell research focuses on subjects like Cell biology, which are linked to Receptor.
His CD28 research is multidisciplinary, incorporating perspectives in Regulatory T cell, Inflammation and CD80. His Cytotoxic T cell study frequently links to related topics such as CD8. Thomas Hünig has researched Antigen in several fields, including Pan-T antigens and Lymphocyte.
Thomas Hünig mainly focuses on Immunology, CD28, Immune system, Antigen and Antibody. His study brings together the fields of Cytotoxic T cell and Immunology. His studies deal with areas such as Regulatory T cell, Monoclonal antibody and Cell biology as well as CD28.
His Antigen study combines topics in areas such as Adoptive cell transfer and Virology. His Antibody research incorporates elements of Receptor, Glomerulonephritis and Human leukocyte antigen. His T cell study incorporates themes from Interleukin 2, Cancer research, Transgene and Immunotherapy.
Thomas Hünig spends much of his time researching Immunology, CD28, T cell, TGN1412 and Autoimmunity. His Immunology study frequently draws parallels with other fields, such as Receptor complex. The concepts of his CD28 study are interwoven with issues in Inflammation, Cancer research, Nuclear localization sequence and Cell biology.
The study incorporates disciplines such as Interleukin 2, Cytotoxic T cell and Cell nucleus in addition to T cell. His TGN1412 research includes elements of Monoclonal antibody and Cytokine. He has included themes like Antigen-presenting cell, Molecular biology, Signal transduction, Cyclic adenosine monophosphate and Regulation of gene expression in his Interleukin 21 study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting.
Hubert Schorle;Thomas Holtschke;Thomas Hünig;Anneliese Schimpl.
A monoclonal antibody to a constant determinant of the rat T cell antigen receptor that induces T cell activation. Differential reactivity with subsets of immature and mature T lymphocytes.
T Hünig;H J Wallny;J K Hartley;A Lawetzky.
Journal of Experimental Medicine (1989)
Alternative pathway activation of T cells by binding of CD2 to its cell-surface ligand
T. Hünig;G. Tiefenthaler;K.-H. Meyer zum Büschenfelde;S. C. Meuer.
A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity.
Magdalena Huber;Sylvia Heink;Henrike Grothe;Anna Guralnik.
European Journal of Immunology (2009)
Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist
Chia-Huey Lin;Thomas Hünig.
European Journal of Immunology (2003)
The Human Immunodeficiency Virus Type 1 (HIV-1) Vpu Protein Interferes with an Early Step in the Biosynthesis of Major Histocompatibility Complex (MHC) Class I Molecules
Thomas Kerkau;Igor Bacik;Jack R. Bennink;Jonathan W. Yewdell.
Journal of Experimental Medicine (1997)
Control of T cell hyperactivation in IL-2-deficient mice by CD4(+)CD25(-) and CD4(+)CD25(+) T cells: evidence for two distinct regulatory mechanisms.
Martina Wolf;Anneliese Schimpl;Thomas Hünig.
European Journal of Immunology (2001)
Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis
Niklas Beyersdorf;Stefanie Gaupp;Karen Balbach;Jens Schmidt.
Journal of Experimental Medicine (2005)
CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: Evidence for functionally distinct forms of CD28
Michael Tacke;Gabriele Hanke;Thomas Hanke;Thomas Hünig.
European Journal of Immunology (1997)
Topological Requirements and Signaling Properties of T Cell–activating, Anti-CD28 Antibody Superagonists
Fred Lühder;Yun Huang;Kevin M. Dennehy;Christine Guntermann.
Journal of Experimental Medicine (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: